RT Journal Article
T1 Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study.
A1 Pala, Elena
A1 Bustamante, Alejandro
A1 Clua-Espuny, Josep Lluis
A1 Acosta, Juan
A1 Gonzalez-Loyola, Felipe
A1 Dos Santos, Sara
A1 Ribas-Segui, Domingo
A1 Ballesta-Ors, Juan
A1 Penalba, Anna
A1 Giralt, Marina
A1 Lechuga-Duran, Iñigo
A1 Gentille-Lorente, Delicia
A1 Pedrote, Alonso
A1 Muñoz, Miguel Angel
A1 Montaner, Joan
K1 Atrial Fibrillation
K1 Electrocardiography, Ambulatory
K1 Spain
AB AFRICAT is a prospective cohort study intending to develop an atrial fibrillation (AF) screening program through the combination of blood markers, rhythm detection devices, and long-term monitoring in our community. In particular, we aimed to validate the use of NT-proBNP, and identify new blood biomarkers associated with AF. Also, we aimed to compare AF detection using various wearables and long-term Holter monitoring. 359 subjects aged 65-75 years with hypertension and diabetes were included in two phases: Phase I (n = 100) and Phase II (n = 259). AF diagnosis was performed by baseline 12-lead ECG, 4 weeks of Holter monitoring (NuuboTM), and/or medical history. An aptamer array including 1310 proteins was measured in the blood of 26 patients. Candidates were selected according to p-value, logFC and biological function to be tested in verification and validation phases. Several screening devices were tested and compared: AliveCor, Watch BP, MyDiagnostick and Fibricheck. AF was present in 34 subjects (9.47%). The aptamer array revealed 41 proteins with differential expression in AF individuals. TIMP-2 and ST-2 were the most promising candidates in the verification analysis, but none of them was further validated. NT-proBNP (log-transformed) (OR = 1.934; p The inclusion and monitoring of a cohort of primary care patients for AF detection, together with the testing of biomarkers and screening devices provided useful lessons about AF screening in our community. An AF screening strategy using rhythm detection devices and short monitoring periods among high-risk patients with high NT-proBNP levels could be feasible.
PB Public Library of Science
YR 2022
FD 2022-08-23
LK http://hdl.handle.net/10668/20432
UL http://hdl.handle.net/10668/20432
LA en
NO Palà E, Bustamante A, Clúa-Espuny JL, Acosta J, González-Loyola F, et bal. Blood-biomarkers and devices for atrial fibrillation screening: Lessons learned from the AFRICAT (Atrial Fibrillation Research In CATalonia) study. PLoS One. 2022 Aug 23;17(8):e0273571.
DS RISalud
RD Apr 6, 2025